Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Revenue (2019 - 2025)

Cyclerion Therapeutics has reported Revenue over the past 6 years, most recently at $875000.0 for Q3 2025.

  • Quarterly results put Revenue at $875000.0 for Q3 2025, up 351.03% from a year ago — trailing twelve months through Sep 2025 was $2.9 million (up 1371.65% YoY), and the annual figure for FY2024 was $2.0 million, changed.
  • Revenue for Q3 2025 was $875000.0 at Cyclerion Therapeutics, up from $93000.0 in the prior quarter.
  • Over the last five years, Revenue for CYCN hit a ceiling of $3.0 million in Q2 2021 and a floor of $62000.0 in Q1 2021.
  • Median Revenue over the past 4 years was $348000.0 (2021), compared with a mean of $728090.9.
  • Biggest five-year swings in Revenue: crashed 93.89% in 2021 and later surged 1046.77% in 2022.
  • Cyclerion Therapeutics' Revenue stood at $533000.0 in 2021, then plummeted by 42.59% to $306000.0 in 2022, then surged by 490.2% to $1.8 million in 2024, then crashed by 51.55% to $875000.0 in 2025.
  • The last three reported values for Revenue were $875000.0 (Q3 2025), $93000.0 (Q2 2025), and $81000.0 (Q1 2025) per Business Quant data.